These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2698453)

  • 1. The dose-effect relationship of 0.5, 1.0 and 1.5 mg fluspirilene on anxious patients.
    Lehmann E
    Neuropsychobiology; 1989; 21(4):197-204. PubMed ID: 2698453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind clinical evaluation of different dose intervals with fluspirilene (IMAP).
    Börger J; Van Epen JH; Dekkers A
    Acta Psychiatr Belg; 1978; 78(2):383-91. PubMed ID: 354325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New long-acting treatment of anxiety and its different forms of somatization: low-dose fluspirilene].
    Giannelli A; Zarattini F
    Minerva Med; 1983 Mar; 74(13):727-33. PubMed ID: 6835561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interaction of therapeutic effects and side effects in drug therapy of generalized anxiety disorders with low dosage fluspirilene].
    Wurthmann C; Klieser E; Lehmann E
    Fortschr Neurol Psychiatr; 1995 Feb; 63(2):72-7. PubMed ID: 7705742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental comparison of low doses of 1.5 mg fluspirilene and bromazepam in out-patients with psychovegetative disturbances.
    Hassel P
    Pharmacopsychiatry; 1985 Sep; 18(5):297-302. PubMed ID: 2864709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Test therapy in the treatment of generalized anxiety disorders with low dose fluspirilene.
    Wurthmann C; Klieser E; Lehmann E; Pester U
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Oct; 19(6):1049-60. PubMed ID: 8584682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose neuroleptanxiolysis in anxiety states.
    Heinrich K; Lehmann E
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):135-43. PubMed ID: 1349757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alternative therapy concept for the treatment of psychosomatic disorders. Controlled double-blind evaluation of fluspirilene versus bromazepam].
    Lehmann E; Hassel P; Thörner GW; Karrass W
    Fortschr Med; 1984 Oct; 102(40):1033-6. PubMed ID: 6149989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation.
    Chouinard G; Annable L; Steinberg S
    J Clin Psychopharmacol; 1986 Feb; 6(1):21-6. PubMed ID: 3512622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluspirilene in schizophrenia maintenance therapy and its interaction with dexetimide].
    Skopová J; Faltus F; Filip V; Jirák R; Karen P; Posmurová M; Dobiásová A
    Cesk Psychiatr; 1985 Dec; 81(6):414-9. PubMed ID: 3912068
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fluspirilene--safe weekly tranquilizer?].
    Kuhn W; Wöhrle M; Müller T; Welter F
    Nervenarzt; 1997 Jun; 68(6):528. PubMed ID: 9312689
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of long-term neuroleptanxiolysis with fluspirilene 1.5 mg per week.
    Tegeler J; Lehmann E; Weiher A; Heinrich K
    Pharmacopsychiatry; 1990 Nov; 23(6):259-64. PubMed ID: 2284327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The 1st injectable weekly tranquilizer--Imap 1,5. Field study on 316 patients].
    Seufert O; Neumann HJ
    Med Welt; 1977 Oct; 28(41):1670-3. PubMed ID: 927131
    [No Abstract]   [Full Text] [Related]  

  • 14. [A comparison of the tranquilizing effect of fluspirilene and diazepam (author's transl)].
    Pach J; Waniek W
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Mar; 9(2):61-6. PubMed ID: 981324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on the tranquilizer effect of fluspirilene and bromazepam].
    Thilmann J
    Med Welt; 1981 Dec; 32(51-52):1959-61. PubMed ID: 6120433
    [No Abstract]   [Full Text] [Related]  

  • 16. Correct titration of non-drugs and some other methodological issues.
    Beneke M; Rasmus W; Rød IS; Fritze J
    Neuropsychobiology; 1994; 30(1):37-41. PubMed ID: 7969857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data.
    Wylie ME; Miller MD; Shear MK; Little JT; Mulsant BH; Pollock BG; Reynolds CF
    J Geriatr Psychiatry Neurol; 2000; 13(1):43-8. PubMed ID: 10753007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders.
    Hanus M; Lafon J; Mathieu M
    Curr Med Res Opin; 2004 Jan; 20(1):63-71. PubMed ID: 14741074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.